Pelvic floor muscle failure and impaired vaginal microbiocenosis: results of combination treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Pelvic floor muscle failure (PFMF) that is manifested by perineal incompetence is concurrent with vaginal dysbiosis in 79% of cases and often has a polymicrobial etiology, which requires appropriate treatment. Case report. The paper describes a clinical case of a female patient diagnosed with PFMF (N81.8). This patient underwent smear microscopy, pH-metry, and evaluation of pelvic floor muscle strength; questionnaires were used. Treatment was performed, which included the combination drug metronidazole/miconazole/lidocaine/viseptol and stimulator-based pelvic floor muscle training. Treatment for dysbiosis was effective when the above drug was administered; there were no recurrences during the follow-up period. Stimulator-based treatment for PFMF could reduce the frequency and severity of symptoms (from 94.8 to 69.8 PFDI-20 scores; p = 0.03) and dyspareunia (from 80 to 20 visual analogue scale scores; p = 0.03), improve sexual function (from 15.3 to 27.2 FSFI scores; p = 0.001), and prevent progressive PFMF and recurrent dysbiosis. Conclusion. The described clinical case showed that the combination treatment of perineal incompetence with the use of stimulators during the pregravidpreparation period could reduce the incidence and severity of symptoms of stress urinary incontinence and dyspareunia, prevent postpartum progressive PFMF, as well as recurrent vaginal dysbiosis, and improve sexual function.

Full Text

Restricted Access

About the authors

Galina B. Dikke

F.I. Inozemtsev Academy of Medical Education

Email: galadikke@yandex.ru
MD, associate professor, professor of the Department of Obstetrics and Gynecology with a course of reproductive medicine.

References

  1. Дикке Г.Б., Кочев Д.М. Дисфункция тазового дна до и после родов и превентивные стратегии в акушерской практике. Акушерство и гинекология. 2016; 5: 9-15. https://dx.doi.org/10.18565/aig.2017.5.9-15.
  2. Memon H.U., Handa V.L. Vaginal childbirth and pelvic floor disorders. Womens Health. 2013; 9(3): 265-77. https://dx.doi.org/10.2217/whe.13.17.
  3. Тотчиев Г.Ф., Токтар Л.Р., Тигиева А.В., Завадина Е.В. Состояние влагалищного биотопа у пациенток репродуктивного возраста, страдающих несостоятельностью тазового дна. Вестник Российского университета дружбы народов. Серия: Медицина. 2013; 5: 146-50.
  4. Хрянин А.А., Решетников О.В. Бактериальный вагиноз. Новые представления о микробном биосоциуме и возможности лечения. Медицинский совет. 2014; 17: 128-32. https://dx.doi.org/10.21518/2079-701X-2014-17-128-133.
  5. Bradshaw C.S., Sobel J.D. Current treatment of bacterial vaginosis-limitations and need for innovation. J. Infect. Dis. 2016; 214(Suppl. 1): 14-20. https:// dx.doi.org/10.1093/infdis/jiw159.
  6. Дикке Г.Б. Алгоритм ранней диагностики и консервативного лечения дисфункции тазового дна: 5 STEPS. М.; 2018. 24 с.
  7. Петухов В.С. Вагинальные конусы и реабилитация тазового дна (обзор литературы). Репродуктивное здоровье Восточная Европа. 2016; 6(2): 232-49.
  8. Дикке Г.Б., Кучерявая Ю.Г., Суханов А.А., Кукарекая И.И., Щербатых Е.Ю. Современные методы оценки функции и силы мышц тазового дна у женщин. Медицинский алфавит. 2019; 1: 80-5.
  9. Российское общество дерматовенерологов и косметологов, Российское общество акушеров-гинекологов. Федеральные клинические рекомендации по ведению больных бактериальным вагинозом. М.; 2015. 15 с.
  10. Российское общество дерматовенерологов и косметологов, Российское общество акушеров-гинекологов. Федеральные клинические рекомендации по ведению больных урогенитальным кандидозом. М.; 2015. 18 с.
  11. Wiegersma M., Panman C.M.C.R., Berger M.Y., De Vet H.C.W., Kollen B.J., Dekkr J.H. Minimal important change in the pelvic floor distress inventory - 20 among women opting for conservative prolapse treatment. Am. J. Obstet. Gynecol. 2017; 216(4): 397. e1-397. e7. https://dx.doi.org/10.1016/j. ajog.2016.10.010.
  12. Rosen R., Brown C., Heiman J., Leiblum S., Meston C., Shabsigh R. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 2000; 26(2): 191-208. https://dx.doi.org/10.1080/009262300278597.
  13. Дикке Г.Б., Аполихина И.А., Кочев Д.М., Щербатых Е.Ю. Распространенность дисфункции тазового дна среди акушеров-гинекологов и факторы, влияющие на выбор терапевтических подходов. Акушерство и гинекология. 2017; 10: 105-13. https://dx.doi.org/10.18565/aig.2017.10.
  14. Sherrard1 J., Donders G., White D., Jensen J.S. European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011. 23р. Available at: http://www.iusti.org/
  15. Truter I., Graz M. Bacterial vaginosis: Literature review of treatment options with specific emphasis on non-antibiotic treatment. Review. Afr. J. Pharm. Pharmacol. 2013; 7(48): 3060-7. https://dx.doi.org/10.5897/AJPPX2013.0001.
  16. De Backer E. Antibiotic susceptibility and molecular diagnosis of Atopobium vaginae, a new pathogen in bacterial vaginosis. Ghent, Belgium: Ghent University. Faculty of Medicine and Health Sciences; 2010. 11 р.
  17. Савичева А.М., Шипицина Е.В. Микробиота влагалища при бактериальном вагинозе. Аспекты диагностики и терапии. Медицинский совет. 2014; 9: 90-4. https://dx.doi.org/10.21518/2079-701X-2014-9-90-95.
  18. Barasch A., Griffin A.V. Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials. Future Microbiol. 2008; 3(3): 265-9. https:// dx.doi.org/10.2217/17460913.3.3.265.
  19. Weese J.S., Walker M., Lowe T. In vitro miconazole susceptibility of meticillin-resistant Staphylococcus pseudintermedius and Staphylococcus aureus. Vet. Dermatol. 2012; 23: 400-2. https://dx.doi.org/10.1111/j.1365-3164.2012.01068.x.
  20. Nenoff P., Koch D., Kruger C., Drechsel C., Mayser P. New insights on the antibacterial efficacy of miconazole in vitro. Mycoses. 2017; 60(8): 552-7. https://dx.doi.org/ 10.1111/myc.12620.
  21. Панкрушева Т.А., Ерофеева Л.Н., Орлова Т.В., Курилова О.О. Суппозитории. Современный взгляд на лекарственную форму. Монография. Курск: КГМУ; 2017. 212 с.
  22. Минаев Н.Н., Провоторова Т.В. Отдаленные результаты применения препарата нео-пенотран форте для лечения пациенток с бактериальным вагинозом. Молодой ученый. 2015; 6: 283-7.
  23. Hagen S., Stark D. Conservative management of pelvic organ prolapse in women. Cochrane Database Syst. Rev. 2011; 12: CD003882. https:// dx.doi.org/10.1002/14651858.CD003882.pub4.
  24. Braekken I.H., Majida M., Engh M.E. Morphological changes after pelvic floor muscle training measured by 3-dimensional ultrasonography: a randomized controlled trial. Obstet Gynecol. 2010; 115(2, Pt 1): 317-24. https://dx.doi. org/10.1097/AOG.0b013e3181cbd35f.
  25. Losada L., Amundsen C.L., Ashton-Miller J., Chai T., Close C., Damaser M. et al. Expert panel recommendations on lower urinary tract health of women across their life Span. J. Womens Health (Larchmt). 2016; 25(11): 1086-96. https:// dx.doi.org/10.1089/jwh.2016.5895.
  26. Серов В.Н., Аполихина И.А., Кубицкая Ю.В., Железнякова А.И. Электростимуляция мышц тазового дна в лечении недержания мочи у женщин. Акушерство и гинекология. 2011; 7-2: 51-5.
  27. Dumoulin C., Hay-Smith J., Habee-Seguin G.M., Mercier J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women: A short version Cochrane systematic review with metaanalysis. Neurourol. Urodyn. 2015; 34(4): 300-8. https://dx.doi.org/10.1002/ nau.22700.
  28. Lipp A., Shaw C., Glavind K. Mechanical devices for urinary incontinence in women. Cochrane Database Syst. Rev. 2014; (12): CD001756. https://dx.doi. org/10.1002/14651858.CD001756.pub6.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies